Assertio (ASRT) Stock Price, News & Analysis

Company Overview

Assertio Therapeutics, Inc., formerly known as Depomed, is a specialty pharmaceutical company focused on the development and commercialization of therapies for central nervous system (CNS) disorders, including neuropathic pain, migraine and breakthrough cancer pain. The company’s commercial portfolio includes three FDA-approved products—Qutenza (8% capsaicin) for postherpetic neuralgia, Butrans (buprenorphine) transdermal system for chronic pain and Onsolis (fentanyl buccal soluble film) for breakthrough cancer pain—which are marketed primarily in the United States under licensing agreements with global partners.

In addition to its marketed therapies, Assertio maintains a pipeline of preclinical and clinical-stage candidates targeting a range of pain and neurological conditions. The firm leverages strategic collaborations to expand its product offerings and enhance patient access. Research and development efforts are supported by a commercial infrastructure that provides sales, marketing and medical affairs support across various U.S. territories.

Founded in 1995 as Depomed, the company rebranded to Assertio Therapeutics in late 2020 following a corporate restructuring designed to sharpen its focus on CNS disorders. Headquartered in Chicago, Illinois, Assertio operates a streamlined corporate structure to optimize efficiency and maintain healthy cash flows while pursuing growth through acquisitions and out-licensing opportunities. Its commercial reach is currently concentrated in North America, with plans to explore additional partnerships for international distribution.

Assertio’s leadership team is led by President and Chief Executive Officer Donald P. Deieso, who has directed the company’s transformation and efforts to revitalize its portfolio. Under Deieso’s guidance, Assertio continues to prioritize disciplined resource allocation and strategic collaboration to drive product innovation and deliver value to patients, healthcare providers and shareholders.

Key Stats

• Today's Range: $22.39 to $22.53
• 50-Day Range: $11.50 to $22.37
• 52-Week Range: $8.61 to $22.53
• Volume: 40,270 shs
• Average Volume: 167,492 shs
• Market Capitalization: $144.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.90
• Consensus Rating: Hold

Assertio Stock Analysis - MarketRank™

Assertio scored higher than 50% of companies evaluated by MarketBeat, and ranked 529th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Assertio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and 1 sell rating.

Downside Risk

Assertio has a consensus price target of $19.90, representing about 11.0% downside from its current price of $22.37.

Amount of Analyst Coverage

Assertio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 3,600.00%

Earnings Growth

Earnings for Assertio are expected to grow by 3,600.00% in the coming year, from $0.03 to $1.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Assertio is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Assertio is -4.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Assertio has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.64% of the float of Assertio has been sold short.

Short Interest Ratio / Days to Cover

Assertio has a short interest ratio ("days to cover") of 1.07, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Assertio has recently decreased by 4.84%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Assertio does not currently pay a dividend.

Dividend Growth

Assertio does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.58

News Sentiment

Assertio has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Assertio this week, compared to 3 articles on an average week.

Search Interest

12 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Assertio insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.70% of the stock of Assertio is held by insiders.

Percentage Held by Institutions

48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 3/16/2026
• Today: 5/08/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASRT
• CIK: 1808665
• Web: www.assertiotx.com
• Phone: (224) 419-7106
• Fax: 510-744-8001
• Employees: 20
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Assertio: $19.90
• High Price Target: $21.80
• Low Price Target: $18.00
• Potential Upside/Downside: -11.6%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 750.17
• P/E Growth: N/A
• Net Income: -$30.38 million
• Net Margins: -25.59%
• Pretax Margin: -25.22%
• Return on Equity: -30.26%
• Return on Assets: -10.59%

Debt

• Debt-to-Equity Ratio: 0.42
• Current Ratio: 1.70
• Quick Ratio: 1.51

Sales & Book Value

• Annual Sales: $118.71 million
• Price / Sales: 1.22
• Cash Flow: $0.02 per share
• Price / Cash Flow: 1,357.78
• Book Value: $14.63 per share
• Price / Book: 1.54

Miscellaneous

• Outstanding Shares: 6,445,000
• Free Float: 6,078,000
• Market Cap: $145.04 million
• Optionable: Optionable
• Beta: 0.44